How much is a CVM stock worth?
Apr 12, 2022 · Real-time trade and investing ideas on CEL-SCI Corp. CVM from the largest community of traders and investors.
Will Cel-Sci (CVM) stock go up or down?
Apr 02, 2022 · CEL-SCI's stock was trading at $9.74 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CVM stock has decreased by 63.3% and is now trading at $3.57. View which stocks have been most impacted by COVID-19.
What does CVM stand for?
This is why. The stock price of CEL-SCI Corporation (NYSE: CVM) increased by over 65% during intraday trading today. Investors are responding positively to a report from Stat News that the company had a private meeting over plans to issue a press release related to its experimental cancer drug Multikine.
Is CVM stock up 60% before the closing bell on Wednesday?
Does CVM stock go up?
During the day the stock fluctuated 11.83% from a day low at $3.26 to a day high of $3.64....Predicted Opening Price for CEL-SCI Corporation of Wednesday, April 13, 2022.Fair opening price April 13, 2022Current price$3.39$3.29 (Undervalued)
Is CVM shorted?
Short Shares Availability This table shows the number of shares of US:CVM available to be shorted at a leading prime brokerage. It is not the total number of shares available to short, nor is it the short interest. It does not include data from other brokers or dark pools.
What happened CEL-SCI?
CEL-SCI plummets 43% after phase 3 immunotherapy data misses primary endpoint. Shares of CEL-SCI Corp. (NYSE:CVM) have plummeted 43% after phase 3 data on its Multikine (leukocyte interleukin) immunotherapy candidate missed its primary endpoint for head and neck cancer.Jun 28, 2021
Why is Cel-Sci stock dropping?
The markets have made their biggest declines since the early uncertainty of the Covid-19 pandemic.
Will multikine get FDA approval?
Multikine has not been licensed or approved by the FDA or by any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.
What is multikine?
A mixture of different immune molecules, potentially simulating the natural immune system: Multikine is composed of a defined mixture of naturally occurring molecules which in early-phase studies have been reported to be biologically/immunologically active.
How has CEL-SCI's stock price been impacted by COVID-19?
CEL-SCI's stock was trading at $9.74 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since th...
When is CEL-SCI's next earnings date?
CEL-SCI is scheduled to release its next quarterly earnings announcement on Monday, May 16th 2022. View our earnings forecast for CEL-SCI .
How were CEL-SCI's earnings last quarter?
CEL-SCI Co. (NYSEAMERICAN:CVM) announced its quarterly earnings data on Wednesday, December, 22nd. The company reported ($0.19) earnings per share...
When did CEL-SCI's stock split? How did CEL-SCI's stock split work?
CEL-SCI's stock reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares own...
Who are CEL-SCI's key executives?
CEL-SCI's management team includes the following people: Mr. Geert R. Kersten , CEO, Principal Accounting & Financial Officer, Treasurer and Dire...
Who are some of CEL-SCI's key competitors?
Some companies that are related to CEL-SCI include Sangamo Therapeutics (SGMO) , Atara Biotherapeutics (ATRA) , Replimune Group (REPL) , Agenus...
What other stocks do shareholders of CEL-SCI own?
Based on aggregate information from My MarketBeat watchlists, some companies that other CEL-SCI investors own include Dynavax Technologies (DVAX)...
What is CEL-SCI's stock symbol?
CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."
Who are CEL-SCI's major shareholders?
CEL-SCI's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (7.79%), Blac...